| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
14 |
| Employees |
13 |
| Revenues (TTM) (Millions $) |
43 |
| Net Income (TTM) (Millions $) |
-101 |
| Cash Flow (TTM) (Millions $) |
-37 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Zyla Life Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies to treat diseases in areas of unmet medical need. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
Zyla Life Sciences has a diverse pipeline of products that focus on the management of neurological and psychiatric disorders, rare diseases, and oncology. The company's lead drug candidate is a potential treatment for Lennox-Gastaut syndrome (LGS), a rare and severe form of epilepsy that usually develops in childhood. LGS is difficult to treat and often requires multiple medications, making it an area of unmet medical need. Zyla's drug candidate has received orphan drug designation from the FDA, which could provide the company with additional benefits if the drug is approved.
In addition to their LGS candidate, Zyla Life Sciences is also developing drugs to treat other neurological and psychiatric disorders, including Huntington's disease, Parkinson's disease, and schizophrenia. The company's oncology pipeline is focused on developing therapies to target cancer cells and improve overall survival rates.
Zyla Life Sciences is committed to advancing science and innovation for the benefit of patients with unmet medical needs. The company is actively pursuing partnerships and collaborations to accelerate the development of its pipeline and bring potentially life-changing treatments to patients in need.
|
%